The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Advances and challenges in therapeutic targeting of NRF2
Open accessAbstract
Activation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation, and metabolic imbalances. These processes underpin many chronic pathologies with unmet therapeutic needs, including neurodegenerative disorders and metabolic diseases. As the NRF2 field transitions into the clinical phase of its evolution, the need for an understanding of the factors influencing NRF2 pharmacology has never been greater. In this opinion article we describe the rationale for targeting NRF2, summarise the recent advances in drug development of NRF2 modulators, and reflect on the remaining challenges in realising the full clinical potential of NRF2 as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Self-citationThe KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
Zhang, Y., Talalay, P., Cho, C. G., & Posner, G. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2399 · Cited by 1,682
NRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationPhosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Ichimura, Y., Waguri, S., Sou, Y.-S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.003 · Cited by 1,205
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995
An open-source drug discovery platform enables ultra-large virtual screens
Gorgulla, C., Boeszoermenyi, A., Wang, Z.-F., Fischer, P. D., Coote, P. W., Padmanabha Das, K. M., Malets, Y. S., Radchenko, D. S., Moroz, Y. S., Scott, D. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2117-z · Cited by 641
Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 569
Self-citationOxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway
Holze, C., Michaudel, C., Mackowiak, C., Haas, D. A., Benda, C., Hubel, P., Pennemann, F. L., Schnepf, D., Wettmarshausen, J., Braun, M., et al. (2018) · Nature Immunology · doi:10.1038/s41590-017-0013-y · Cited by 452
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
Saito, T., Ichimura, Y., Taguchi, K., Suzuki, T., Mizushima, T., Takagi, K., Hirose, Y., Nagahashi, M., Iso, T., Fukutomi, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12030 · Cited by 362
Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis
Kang, Y. P., Mockabee-Macias, A., Jiang, C., Falzone, A., Prieto-Farigua, N., Stone, E., Harris, I. S., & DeNicola, G. M. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.007 · Cited by 349
Broccoli or Sulforaphane: Is It the Source or Dose That Matters?
Yagishita, Y., Fahey, J. W., Dinkova-Kostova, A. T., & Kensler, T. W. (2019) · Molecules · doi:10.3390/molecules24193593 · Cited by 347
Self-citationSafety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
Lynch, D. R., Chin, M. P., Delatycki, M. B., Subramony, S. H., Corti, M., Hoyle, J. C., Boesch, S., Nachbauer, W., Mariotti, C., Mathews, K. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25934 · Cited by 332
Axelsson, A. S., Tubbs, E., Mecham, B., Chacko, S., Nenonen, H. A., Tang, Y., Fahey, J. W., Derry, J. M. J., Wollheim, C. B., Wierup, N., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4477 · Cited by 323
Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00228 · Cited by 322
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Beyond repression of Nrf2: An update on Keap1
Kopacz, A., Kloska, D., Forman, H. J., Jozkowicz, A., & Grochot-Przeczek, A. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.023 · Cited by 265
Hast, B. E., Goldfarb, D., Mulvaney, K. M., Hast, M. A., Siesser, P. F., Yan, F., Hayes, D. N., & Major, M. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4400 · Cited by 259
Sayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife · doi:10.7554/elife.28083 · Cited by 231
Dinkova-Kostova, A. T., Jenkins, S. N., Fahey, J. W., Ye, L., Wehage, S. L., Liby, K. T., Stephenson, K. K., Wade, K. L., & Talalay, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.09.012 · Cited by 230
Self-citationBest, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H., Ritchie, M. E., McConville, M. J., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.006 · Cited by 217
Sharma, R. S., Harrison, D. J., Kisielewski, D., Cassidy, D. M., McNeilly, A. D., Gallagher, J. R., Walsh, S. V., Honda, T., McCrimmon, R. J., Dinkova-Kostova, A. T., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.016 · Cited by 213
Self-citationA small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
Ghergurovich, J. M., García-Cañaveras, J. C., Wang, J., Schmidt, E., Zhang, Z., TeSlaa, T., Patel, H., Chen, L., Britt, E. C., Piqueras-Nebot, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0533-x · Cited by 210
Egner, P. A., Chen, J.-G., Zarth, A. T., Ng, D. K., Wang, J.-B., Kensler, K. H., Jacobson, L. P., Muñoz, A., Johnson, J. L., Groopman, J. D., et al. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0103 · Cited by 191
Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism
Horie, Y., Suzuki, T., Inoue, J., Iso, T., Wells, G., Moore, T. W., Mizushima, T., Dinkova-Kostova, A. T., Kasai, T., Kamei, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02100-6 · Cited by 189
Self-citationSussan, T. E., Jun, J., Thimmulappa, R., Bedja, D., Antero, M., Gabrielson, K. L., Polotsky, V. Y., & Biswal, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003791 · Cited by 179
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
Lynch, D. R., Farmer, J., Hauser, L., Blair, I. A., Wang, Q. Q., Mesaros, C., Snyder, N., Boesch, S., Chin, M., Delatycki, M. B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.660 · Cited by 173
Matzinger, M., Fischhuber, K., Pölöske, D., Mechtler, K., & Heiß, E. H. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101393 · Cited by 148
Tao, S., de la Vega, M. R., Chapman, E., Ooi, A., & Zhang, D. D. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22745 · Cited by 145
Quinti, L., Dayalan Naidu, S., Träger, U., Chen, X., Kegel-Gleason, K., Llères, D., Connolly, C., Chopra, V., Low, C., Moniot, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614943114 · Cited by 140
Self-citationDimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Linker, R. A., & Haghikia, A. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316653307 · Cited by 139
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
Pakpoor, J., Disanto, G., Altmann, D. R., Pavitt, S. H., Turner, B. P., Marta, M., Juliusson, G., Baker, D., Chataway, J., & Schmierer, K. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000158 · Cited by 137
Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans
Knatko, E. V., Ibbotson, S. H., Zhang, Y., Higgins, M., Fahey, J. W., Talalay, P., Dawe, R. S., Ferguson, J., Huang, J. T.-J., Clarke, R. G., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0362 · Cited by 126
Self-citationLiu, H., Dinkova‐Kostova, A. T., & Talalay, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808346105 · Cited by 122
Self-citationCurrent Landscape of NRF2 Biomarkers in Clinical Trials
Yagishita, Y., Gatbonton-Schwager, T. N., McCallum, M. L., & Kensler, T. W. (2020) · Antioxidants · doi:10.3390/antiox9080716 · Cited by 117
Ryan, D. G., Knatko, E. V., Casey, A. M., Hukelmann, J. L., Naidu, S. D., Brenes, A. J., Ekkunagul, T., Baker, C. P., Higgins, M., Tronci, L., et al. (2021) · iScience · doi:10.1016/j.isci.2022.103827 · Cited by 116
Self-citationZimmerman, A. W., Singh, K., Connors, S. L., Liu, H., Panjwani, A. A., Lee, L.-C., Diggins, E., Foley, A., Melnyk, S., Singh, I. N., et al. (2021) · Molecular Autism · doi:10.1186/s13229-021-00447-5 · Cited by 111
The NRF 2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Hammer, A., Waschbisch, A., Kuhbandner, K., Bayas, A., Lee, D., Duscha, A., Haghikia, A., Gold, R., & Linker, R. A. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.553 · Cited by 110
The absence of macrophage Nrf2 promotes early atherogenesis
Ruotsalainen, A.-K., Inkala, M., Partanen, M. E., Lappalainen, J. P., Kansanen, E., Mäkinen, P. I., Heinonen, S. E., Laitinen, H. M., Heikkilä, J., Vatanen, T., et al. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt008 · Cited by 109
Tran, K. T., Pallesen, J. S., Solbak, S. M. Ø., Narayanan, D., Baig, A., Zang, J., Aguayo‐Orozco, A., Carmona, R. M., Garcia, A. D., & Bach, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00723 · Cited by 108
Spencer, S. R., Wilczak, C. A., & Talalay, P. (1990) · PubMed · Cited by 102
Naidu, S. D., Muramatsu, A., Saito, R., Asami, S., Honda, T., Hosoya, T., Itoh, K., Yamamoto, M. P., Suzuki, T., & Dinkova‐Kostova, A. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26269-9 · Cited by 102
Self-citationExploring the target scope of KEAP1 E3 ligase-based PROTACs
Du, G., Jiang, J., Henning, N. J., Safaee, N., Koide, E., Nowak, R. P., Donovan, K. A., Yoon, H., You, I., Yue, H., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.003 · Cited by 99
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Ding, H., Chen, Z., Wu, K., Huang, S. M., Wu, W., LeBoeuf, S. E., Pillai, R., Rabinowitz, J. D., & Papagiannakopoulos, T. Y. (2021) · Science Advances · doi:10.1126/sciadv.abk1023 · Cited by 98
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
Okazaki, K., Anzawa, H., Liu, Z., Ota, N., Kitamura, H., Onodera, Y., Alam, M. M., Matsumaru, D., Suzuki, T., Katsuoka, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19593-0 · Cited by 93
Bathish, B., Robertson, H., Dillon, J. F., Dinkova‐Kostova, A. T., & Hayes, J. D. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.06.226 · Cited by 72
Self-citationDimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex
Zaro, B. W., Vinogradova, E. V., Lazar, D. C., Blewett, M. M., Suciu, R. M., Takaya, J., Studer, S., de la Torre, J. C., Casanova, J.-L., Cravatt, B. F., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801627 · Cited by 68
Liu, H., Zimmerman, A. W., Singh, K., Connors, S. L., Diggins, E., Stephenson, K. K., Dinkova‐Kostova, A. T., & Fahey, J. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-62714-4 · Cited by 65
Self-citationRiess, J. W., Frankel, P. H., Shackelford, D. B., Dunphy, M. P., Badawi, R. D., Nardo, L., Cherry, S. R., Lanza, I. R., Reid, J. M., Gonsalves, W. I., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.006 · Cited by 63
Richardson, B. G., Jain, A. D., Potteti, H. R., Lazzara, P. R., David, B. P., Tamatam, C. R., Choma, E., Skowron, K. J., Dye, K., Siddiqui, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01133 · Cited by 57
Lazzara, P. R., David, B. P., Ankireddy, A., Richardson, B. G., Dye, K., Ratia, K. M., Reddy, S. P., & Moore, T. W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01074 · Cited by 56
Ruotsalainen, A., Lappalainen, J. P., Heiskanen, E., Merentie, M., Sihvola, V., Näpänkangas, J. P., Lottonen‐Raikaslehto, L., Kansanen, E., Adinolfi, S., Kaarniranta, K., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy143 · Cited by 45
Design and characterization of a heterobifunctional degrader of KEAP1
Chen, H., Nguyen, N. H., Magtoto, C. M., Cobbold, S. A., Bidgood, G. M., Guzman, L. G. M., Richardson, L. W., Corbin, J. E., Au, A. E., Lechtenberg, B. C., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102552 · Cited by 43
Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 42
Lewis, J. H., Jadoul, M. Y., Block, G. A., Chin, M. P., Ferguson, D. A., Goldsberry, A., Meyer, C. J., O’Grady, M., Pérgola, P. E., Reisman, S. A., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12868 · Cited by 41
Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera
Poganik, J. R., Huang, K., Parvez, S., Zhao, Y., Raja, S., Long, M. J. C., & Aye, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-25466-x · Cited by 35
Diskin, C., Zotta, A., Corcoran, S. E., Tyrrell, V. J., Zasłona, Z., O’Donnell, V. B., & O'Neill, L. A. J. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100488 · Cited by 34
Liver injury associated with dimethyl fumarate in multiple sclerosis patients
Muñoz, M. A., Kulick, C. G., Kortepeter, C. M., Levin, R. L., & Avigan, M. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516688351 · Cited by 33
Naidu, S. D., Suzuki, T., Dikovskaya, D., Knatko, E. V., Higgins, M., Sato, M., Novak, M. J., Villegas, J. A., Moore, T. W., Yamamoto, M. P., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103703 · Cited by 33
Self-citationGeorgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00457 · Cited by 33
Self-citationSauerland, M. B., & Davies, M. J. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109344 · Cited by 32
Liu, J., Cui, J. Y., Lu, Y., Corton, J. C., & Klaassen, C. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000181 · Cited by 23
A systems approach reveals species differences in hepatic stress response capacity
Russomanno, G., Sison-Young, R. L. C., Livoti, L. A., Coghlan, H., Jenkins, R. E., Kunnen, S. J., Fisher, C., Reddyhoff, D., Gardner, I. B., Rehman, A. H., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad085 · Cited by 18
Self-citationChurch, R. J., & Watkins, P. B. (2020) · Clinical and Translational Science · doi:10.1111/cts.12900 · Cited by 8
Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer
Knatko, E. V., Castro, C., Higgins, M., Zhang, Y., Honda, T., Henderson, C. J., Wolf, C. R., Griffin, J. L., & Dinkova‐Kostova, A. T. (2021) · Communications Biology · doi:10.1038/s42003-021-02552-w · Cited by 7
Self-citation
Cited by
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Jawahar Deen, A., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A.-L. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 292
Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis
Młynarska, E., Bojdo, K., Frankenstein, H., Krawiranda, K., Kustosik, N., Lisińska, W., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010096 · Cited by 87
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Self-citationHushpulian, D. M., Kaidery, N. A., Soni, P., Poloznikov, A. A., Zakhariants, A. A., Razumovskaya, A. V., Silkina, M. O., Tishkov, V. I., Kazakov, E. H., Brown, A. M., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103794 · Cited by 8
Metadata
- Authors
- Dinkova-Kostova, A. T., & Copple, I. M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 44
- Issue
- 3
- Pages
- 137-149
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W4313825915
- Cited by
- 266
- References
- 69
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.